Quest Diagnostics Incorporated

• DGX Stock Price 24h change: -2.28%. From 189.02 USD to 184.65 USD. The decline was attributed to a general pull-back after a period of gains, despite the company's inclusion in a major industry "Most Admired" list.
• From a technical perspective, DGX is showing a "Strong Buy" configuration on longer-term moving averages (MA20, MA50, MA200), though short-term momentum (MA5, MA10) suggests a temporary cooling or sideways movement. The 14-day RSI stands at approximately 72.0, indicating the stock is entering overbought territory and may face further consolidation.
• Quest Diagnostics was named to the Fortune 2026 World's Most Admired Companies list on Jan 21, ranking second in its industry category for the 12th consecutive year.
• The company announced expanded national access to the Visby Medical at-home Women's Sexual Health Test to improve rapid STI testing convenience.
• Institutional activity remains high; Boston Common Asset Management reported boosting its stake in DGX by over 26% according to recent SEC filings.
• The global Healthcare IT and Diagnostics market is projected to reach approximately $880 billion by 2030, driven by a 38% CAGR in AI-integrated clinical tools.
• Analysts at the J.P. Morgan Healthcare Conference highlighted that 79% of major health systems have increased investments in digital diagnostic solutions this year.

• DGX Stock Price 24h change: -0.28%. From 189.49 USD to 188.95 USD. (As of Jan 20, 2026).
• From a technical perspective, DGX presents a "Strong Buy" signal: the stock is maintaining a bullish stance with a 14-day RSI of 68.42 (approaching overbought but showing strong momentum) and its price remains above both the 50-day ($181.21) and 200-day ($179.61) moving averages, suggesting a sustained long-term uptrend despite minor daily fluctuations.
• Quest Diagnostics partnered with Visby Medical on January 21, 2026, to launch a new at-home, FDA-authorized PCR test for women's sexual health, expanding its consumer-initiated testing portfolio.
• Quest Diagnostics announced it will release its fourth quarter and full-year 2025 financial results on February 10, 2026.
• The stock traded ex-dividend on January 13, 2026, for a $0.80 per share quarterly cash dividend payable on January 28.
• Boston Scientific (BSX) announced a massive $14.5 billion deal to acquire Penumbra (PEN) on January 20, 2026, signaling a wave of high-value strategic consolidation within the vascular and neurovascular healthcare sectors.
• At the J.P. Morgan Healthcare Conference on January 20, 2026, industry leaders highlighted AI's transition from "hype" to "operational ROI," with Anthropic launching a dedicated "Claude for Healthcare" to automate administrative and clinical workflows for health systems.